Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Wednesday, August 15, 2018 · 458,815,097 Articles · 3+ Million Readers

Microbot Medical’s CEO to Speak as an Industry Expert at the YJP CEO Healthcare Symposium

Discussion to Focus on the Role of Robotics in Healthcare

HINGHAM, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that Harel Gadot, CEO, President and Chairman, will be a featured VIP speaker at the Young Jewish Professional (YJP) CEO Healthcare Forum being held in New York City on February 12th and 13th. The YJP CEO Healthcare Symposium brings together top executives from across the healthcare spectrum to discuss the current and future market trends that are shaping the industry. The topic of Mr. Gadot’s speech will be the role of robotics in healthcare.

Mr. Gadot is a seasoned executive and entrepreneur in the healthcare space, with an extensive and proven track record in medical devices, with specific focus on medical robotics.  He brings over 17 years of experience in leadership positions in the corporate world as well as the start-up sector, in the United States, Europe and Israel, and serves as its Group Chairman.  He is currently the CEO, President and Chairman of Microbot Medical Inc. (NASDAQ:MBOT), a company he co-founded in 2011 and led through its successful listing on NASDAQ in 2016. He is also the Founder and Chairman of privately-held XACT Robotics Ltd., a promising early stage medical robotics venture, the Founder and Group Chairman of MEDX Ventures Group, a unique investment and management firm, as well as the Founder and Chairman of MEDX Xelerator LP, a government supported medical devices incubator in Israel and a partnership between MEDX Ventures Group, Boston Scientific Corporation, Intellectual Ventures and Sheba Medical Center. Mr. Gadot had previously served on the board of directors of ConTIPI Ltd., and played an instrumental role in its business development efforts, leading to its acquisition by Kimberly Clark Corporation in 2012.

Until 2010, Mr. Gadot held roles of increasing responsibility at Johnson & Johnson, including the position of a Worldwide Group Marketing Director at Ethicon Inc., (a Johnson & Johnson (company), overseeing its global strategic marketing. Prior to this, he was the Regional Marketing Manager at Johnson & Johnson (Ethicon Inc., Paris, France), responsible for the strategic marketing for Europe, Middle East and Africa. During his tenure, both companies enjoyed continuous growth in revenue and new product launches (both from internal R&D and M&A). Prior to this, he held several management positions in marketing and sales at Johnson & Johnson Medical Israel.

A former professional basketball player, Mr. Gadot played for numerous professional teams in the Israeli and European leagues. Prior to turning professional, he played at Siena College for the Siena Saints, an NCAA Division I Basketball Program. Harel is often a guest speaker for management, innovation and entrepreneurship courses at leading universities in the United States and Israel, including the Technion - Israel Institute of Technology. He holds a Bachelor of Science (BS) from Siena College (USA) and a Master in Business Administration (MBA) from Manchester University (UK).

/EIN News/ -- About Microbot Medical, Inc.

Microbot was founded in 2010, which commenced operations in 2011, and became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot’s current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.

The ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body.  Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system.  Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time.  To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/.

TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract.  Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body.  To learn more about TipCAT visit http://www.microbotmedical.com/technology/tipcat/.

Safe Harbor

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, the outcome of its further evaluation of the CardioSert technology, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Microbot Medical Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.’s filings with the Securities and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking statements.

Investor Contacts:

Analysts and Institutional Investors
Michael Polyviou
EVC Group
mpolyviou@evcgroup.com
646-445-4800

Individual Investors
Jeremy Roe
Integra Consulting Group llc
jeremy@integracg.net
(925) 262-8305

 

Primary Logo

Powered by EIN News